Patient Involvement in the Design of an Innovative Clinical Study to Compare the Palatability of Anti-Hyperkalemia Medications

DOI: https://doi.org/10.2147/ppa.s445399
2024-05-31
Patient Preference and Adherence
Abstract:Henning Søndergaard Danish Kidney Association, Taastrup, Denmark Correspondence: Henning Søndergaard, Danish Kidney Association, Blekinge Blvd. 2, 2630 Taastrup, Denmark, Tel +45 61654865, Email The inclusion of patient representatives as study consultants brings diverse perspectives, insights, and experiences to clinical trial design and execution, and their role in the clinical trial development process is being increasingly recognized and valued. The APPETIZE study evaluated the palatability of, and preference for, three potassium binders for treating hyperkalemia in patients with chronic kidney disease. A core aspect of the development of this study was the inclusion of a patient representative during the design stage. Here, I describe the process of patient involvement in the APPETIZE study design (ClinicalTrials.gov Identifier: NCT04566653), the resultant positive impacts, and key learnings. A patient with chronic kidney disease was invited to be a member of the APPETIZE trial design team. This patient representative attended study team meetings and provided invaluable input into protocol development, questionnaire selection, design of patient information sheets and consent forms, and primary manuscript structure. These critical insights resulted in an enhanced trial design and generation of high-quality, patient-relevant data. APPETIZE provides an excellent example of a patient preference study that relied on input from multiple stakeholder groups, including, most notably, the patients themselves. This approach may serve as a model for early and deep patient engagement in the design and interpretation of clinical trials. Keywords: clinical trials, patient representation, chronic kidney disease, hyperkalemia Patient participation in and contribution to the drug development cycle has historically been restricted to post-approval disease education. 1 Traditional approaches to clinical trial design considered the disease symptoms of a patient in isolation from the patient as an individual, with the primary role of the patient to adhere to prescribed treatment. 2,3 Recent changes have seen an evolution of the medical field from a "paternalistic" medical model towards a more "patient-centric" one. 2–4 Once patients are thought of as individuals rather than as a collection of clinical symptoms or laboratory values, the patient voice becomes more relevant and it becomes essential to involve patients as consultants in the design of clinical studies. Patient centricity has been defined, during consultation with key stakeholders, patients, and carers, as "putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family". 1 Patient centricity does not need to be confined solely to the healthcare setting; patient involvement and engagement can and should also be incorporated into research and all aspects of the clinical trial lifecycle (Figure 1). 5,6 The value of experience provided by patients is highlighted by the Patient-Centered Outcomes Research Institute (PCORI), who recommend that "meaningful involvement" of patients, caregivers, and clinicians should occur in the planning and conduct of clinical trials. 7 Figure 1 Patient involvement across the clinical trial lifecycle. In this paper, I introduce the importance of patient centricity in clinical trial design before summarizing the process, key changes, and lessons learned from involvement of a patient representative in the design of the APPETIZE clinical trial. Patient centricity and engagement in the context of clinical trials confers a number of benefits to different stakeholders (Figure 2). 8,9 Benefits to patients include enhanced engagement, because patient inclusion as consultants in clinical trial development offers a sense of empowerment, resulting in a more positive trial experience. 9,10 There can also be a reduced burden and improved convenience with respect to study assessments, such as flexible appointment schedules, remote monitoring options, and decreased travel requirements. 11 Patient involvement in the development of trial communication materials allows for the inclusion of more relevant information from lived patient experiences, and facilitates improved patient understanding through the use of plain language. 6,12,13 Patient representatives are well-positioned to advise on the most relevant patient-centered outcome measures, which can include improvements in health-related quality of life, symptom relief, mental health, and functional capacity, and can help ensure that trials are better able to capture the overall impact of the intervention on patients' lives. 9,12,13 Data on patient -Abstract Truncated-
medicine, general & internal
What problem does this paper attempt to address?